LABELS · ea75a39e-4a14-4785-b276-5094b5af1a35

Docetaxel

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2023-11-21
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions ( 5.1 )] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions ( 5.2 )] . Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions ( 5.3 )] . Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications ( 4 )] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [see Warnings and Precautions ( 5.5 )] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions ( 5.6 )] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION See full prescribing information for complete boxed warning. • Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m 2 ( 5.1 ) • Avoid use of docetaxel if bilirubin > ULN, or if AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) • Do not administer docetaxel to patients with neutrophil counts < 1500 cells/ mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) • Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) • Contraindicated if history of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80 ( 4 ) • Severe fluid retention may occur despite dexamethasone ( 5.6 )

Indications and usage: exact source text

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Full extracted label fields

application numbers

NDA201525

boxed warning exact

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions ( 5.1 )] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions ( 5.2 )] . Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions ( 5.3 )] . Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications ( 4 )] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [see Warnings and Precautions ( 5.5 )] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions ( 5.6 )] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION See full prescribing information for complete boxed warning. • Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m 2 ( 5.1 ) • Avoid use of docetaxel if bilirubin > ULN, or if AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) • Do not administer docetaxel to patients with neutrophil counts < 1500 cells/ mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) • Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) • Contraindicated if history of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80 ( 4 ) • Severe fluid retention may occur despite dexamethasone ( 5.6 )

brand names

Docetaxel

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970

generic names

DOCETAXEL

ea75a39e-4a14-4785-b276-5094b5af1a35

indications and usage exact

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

indications and usage tables exact

is original packager

true

manufacturer names

Baxter Healthcare Corporation

matched search terms

cancer
carcinoma

package ndcs

43066-001-01
43066-006-01
43066-010-01

product ndcs

43066-001
43066-006
43066-010

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1093280

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 202
end exclusive: true
exact text: 1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxor
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 0

current approval status

not_reconciled

duplicate text group

dup-4f6d45e4abc89b3093f9

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-341066d1df70823de0c9

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 2
end exclusive: true
exact text: 1.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · indication intro context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 286
end exclusive: true
exact text: 1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 0

current approval status

not_reconciled

duplicate text group

dup-6e734a2074e63382295c

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-3db122e5af4f64890d82

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 81
end exclusive: true
exact text: is a microtubule inhibitor indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 45

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 86
end exclusive: true
exact text: INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for:
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 3

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 488
end exclusive: true
exact text: 1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreat
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 0

current approval status

not_reconciled

duplicate text group

dup-6b8ab02011087f506364

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-4c988ffa5349e695889a

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

context exact
• Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant trea
kind
biomarker
polarity
not_inferred
span
end
186
end exclusive
true
exact text
metastatic BC after chemotherapy failure
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
146
context exact
• Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adju
kind
stage_or_setting
polarity
not_inferred
span
end
177
end exclusive
true
exact text
locally advanced or metastatic BC after chemotherap
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
126
context exact
erapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 )
kind
stage_or_setting
polarity
not_inferred
span
end
276
end exclusive
true
exact text
adjuvant treatment of operable node-positiv
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
233

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 288
end exclusive: true
exact text: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 )
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 87

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 704
end exclusive: true
exact text: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated,
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 89

current approval status

not_reconciled

duplicate text group

dup-815c42b0009b6b6119a7

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-abb5ef5b6ada67c09825

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

context exact
l Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced
kind
biomarker
polarity
not_inferred
span
end
407
end exclusive
true
exact text
metastatic NSCLC after platinum therapy fai
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
364
context exact
e; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
biomarker
polarity
not_inferred
span
end
500
end exclusive
true
exact text
metastatic untreated NSCLC ( 1
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
470
context exact
• Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, local
kind
stage_or_setting
polarity
not_inferred
span
end
395
end exclusive
true
exact text
locally advanced or metastatic NSCLC after platinum
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
344
context exact
SCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
stage_or_setting
polarity
not_inferred
span
end
448
end exclusive
true
exact text
unresectable
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
436
context exact
tinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
stage_or_setting
polarity
not_inferred
span
end
500
end exclusive
true
exact text
locally advanced or metastatic untreated NSCLC ( 1
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
450

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 504
end exclusive: true
exact text: • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 289

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 826
end exclusive: true
exact text: Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 305

current approval status

not_reconciled

duplicate text group

dup-1681369bf962f0a0c882

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-38654770f340f2b7c21a

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
kind
biomarker
polarity
not_inferred
span
end
614
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
571
context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
kind
stage_or_setting
polarity
not_inferred
span
end
616
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
571

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 626
end exclusive: true
exact text: • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 505

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 965
end exclusive: true
exact text: atin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated fo
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 427

current approval status

not_reconciled

duplicate text group

dup-342a7d8c49657cdf0fea

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-ee0f3b2ae36671711e42

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

context exact
cinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 )
kind
stage_or_setting
polarity
not_inferred
span
end
716
end exclusive
true
exact text
advanced GC
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
705

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 765
end exclusive: true
exact text: • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 )
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 627

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA201525

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1111
end exclusive: true
exact text: e in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combinat
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 566

current approval status

not_reconciled

duplicate text group

dup-06d50a5c165ae1216d1b

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-c33db3a66d45677bfdb7

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

Source null

qualifier mentions

context exact
with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
907
end exclusive
true
exact text
locally advanced SCCHN ( 1
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
881

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 911
end exclusive: true
exact text: • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 766

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1279
end exclusive: true
exact text: d GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 712

current approval status

not_reconciled

duplicate text group

dup-5b890729a5f2c7e7c70e

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-5a369b608ccd45ded5aa

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 962
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 950

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1061
end exclusive
true
exact text
metastatic breast cancer after failure of p
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1018
context exact
l Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1049
end exclusive
true
exact text
locally advanced or metastatic breast cancer after
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
998

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 1079
end exclusive: true
exact text: 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 912

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1447
end exclusive: true
exact text: locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior p
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 880

current approval status

not_reconciled

duplicate text group

dup-d68792937e5569c6f65e

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-368f0a113a8887b1b514

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 1165
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1153

qualifier mentions

context exact
with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1217
end exclusive
true
exact text
adjuvant treatment of patients with operabl
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1174
context exact
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
regimen
polarity
not_inferred
span
end
1246
end exclusive
true
exact text
in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1100

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 1247
end exclusive: true
exact text: Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1080

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1674
end exclusive: true
exact text: failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1048

current approval status

not_reconciled

duplicate text group

dup-83b696b7ffb2f2085513

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-845fcb0e4534eb9a3100

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 1329
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1317

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1428
end exclusive
true
exact text
metastatic non-small cell lung cancer after
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1385
context exact
ingle agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1416
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1365
context exact
1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1473
end exclusive
true
exact text
as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1299

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 1474
end exclusive: true
exact text: 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1248

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 11 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1910
end exclusive: true
exact text: cer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Doce
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1275

current approval status

not_reconciled

duplicate text group

dup-a8ca09d4ae8809efe44d

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-9bb881cb86ce265a144b

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 1537
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1525

qualifier mentions

context exact
reatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
biomarker
polarity
not_inferred
span
end
1650
end exclusive
true
exact text
metastatic non-small cell lung cancer who h
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1607
context exact
h cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer
kind
stage_or_setting
polarity
not_inferred
span
end
1585
end exclusive
true
exact text
unresectable
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1573
context exact
indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for thi
kind
stage_or_setting
polarity
not_inferred
span
end
1638
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1587
context exact
Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
regimen
polarity
not_inferred
span
end
1674
end exclusive
true
exact text
in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1495

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 1710
end exclusive: true
exact text: Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1475

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2078
end exclusive: true
exact text: ith cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1511

current approval status

not_reconciled

duplicate text group

dup-deeea0461d273b4b42dc

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-528416a17affb33b4286

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 1794
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1782

qualifier mentions

context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
biomarker
polarity
not_inferred
span
end
1873
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1830
context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1875
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1830
context exact
1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
regimen
polarity
not_inferred
span
end
1877
end exclusive
true
exact text
in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1751

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 1878
end exclusive: true
exact text: 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1711

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 13 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2375
end exclusive: true
exact text: hemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the h
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1679

current approval status

not_reconciled

duplicate text group

dup-e1db18f76f31e895c437

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-401aaddfe3b0ba98ae5a

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 1985
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1973

qualifier mentions

context exact
luorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction,
kind
stage_or_setting
polarity
not_inferred
span
end
2052
end exclusive
true
exact text
advanced gastric adenocarcinoma
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
2021
context exact
geal junction, who have not received prior chemotherapy for advanced disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2174
end exclusive
true
exact text
advanced disease
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
2158
context exact
1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advance
kind
regimen
polarity
not_inferred
span
end
2105
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal ju
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
1926

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 2175
end exclusive: true
exact text: 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1879

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 14 · positive indication candidate

application numbers

NDA201525

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2396
end exclusive: true
exact text: indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 1976

current approval status

not_reconciled

duplicate text group

dup-08e647fe21098f2fae2b

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-0f17312b23da7c1a3f3f

label id

ea75a39e-4a14-4785-b276-5094b5af1a35

positive predicate support span

end: 2280
end exclusive: true
exact text: is indicated
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 2268

qualifier mentions

context exact
l is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
stage_or_setting
polarity
not_inferred
span
end
2377
end exclusive
true
exact text
locally advanced squamous cell carcinoma of the hea
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
2326
context exact
1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
regimen
polarity
not_inferred
span
end
2395
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
2221

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
325
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start
291

source span

end: 2396
end exclusive: true
exact text: 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: ea75a39e-4a14-4785-b276-5094b5af1a35
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a14790f24cdfd70da03703868c95290a536e1ab8f89c60cfa5b6db0eff215d73
start: 2176

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea75a39e-4a14-4785-b276-5094b5af1a35%22

spl effective date

2023-11-21

spl set id

0e0f06bd-d190-45da-be8b-062e8de01970

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice